Brokerages Expect Insmed Incorporated (NASDAQ:INSM) to Announce -$0.67 EPS


Share on StockTwits

Analysts forecast that Insmed Incorporated (NASDAQ:INSM) will announce earnings of ($0.67) per share for the current quarter, Zacks reports. Four analysts have issued estimates for Insmed’s earnings, with the lowest EPS estimate coming in at ($0.79) and the highest estimate coming in at ($0.54). Insmed reported earnings per share of ($0.59) during the same quarter last year, which would suggest a negative year over year growth rate of 13.6%. The business is scheduled to report its next quarterly earnings results on Tuesday, February 23rd.

According to Zacks, analysts expect that Insmed will report full year earnings of ($2.64) per share for the current fiscal year, with EPS estimates ranging from ($2.79) to ($2.49). For the next fiscal year, analysts forecast that the business will post earnings of ($2.64) per share, with EPS estimates ranging from ($3.40) to ($2.28). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Insmed.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.04). Insmed had a negative net margin of 145.14% and a negative return on equity of 79.58%. The business had revenue of $43.64 million during the quarter, compared to analysts’ expectations of $46.07 million. During the same period in the previous year, the company posted ($0.68) earnings per share. Insmed’s quarterly revenue was up 12.2% on a year-over-year basis.

A number of brokerages have recently commented on INSM. Stifel Nicolaus assumed coverage on shares of Insmed in a report on Monday, October 12th. They issued a “buy” rating and a $44.00 target price for the company. SVB Leerink increased their price target on shares of Insmed from $51.00 to $55.00 and gave the stock an “outperform” rating in a report on Monday, January 4th. Berenberg Bank assumed coverage on shares of Insmed in a report on Thursday, December 17th. They set a “buy” rating and a $48.00 price target for the company. Evercore ISI reissued an “outperform” rating and set a $60.00 price target on shares of Insmed in a report on Monday, November 23rd. Finally, Zacks Investment Research cut shares of Insmed from a “hold” rating to a “sell” rating in a report on Wednesday. One analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $47.40.

In other Insmed news, Director Alfred Altomari sold 20,000 shares of the company’s stock in a transaction dated Monday, December 7th. The shares were sold at an average price of $39.57, for a total transaction of $791,400.00. Following the transaction, the director now directly owns 20,938 shares in the company, valued at $828,516.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO William Lewis sold 200,000 shares of the stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $34.03, for a total transaction of $6,806,000.00. Following the completion of the sale, the chief executive officer now owns 129,787 shares in the company, valued at $4,416,651.61. The disclosure for this sale can be found here. Insiders have sold 250,000 shares of company stock worth $8,625,800 over the last 90 days. 4.63% of the stock is currently owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in INSM. Meeder Asset Management Inc. boosted its position in Insmed by 181.5% during the third quarter. Meeder Asset Management Inc. now owns 2,778 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 1,791 shares during the last quarter. Scout Investments Inc. grew its position in Insmed by 20.9% in the third quarter. Scout Investments Inc. now owns 284,255 shares of the biopharmaceutical company’s stock valued at $9,136,000 after acquiring an additional 49,161 shares during the last quarter. Nuveen Asset Management LLC grew its position in Insmed by 4.1% in the second quarter. Nuveen Asset Management LLC now owns 575,328 shares of the biopharmaceutical company’s stock valued at $15,845,000 after acquiring an additional 22,894 shares during the last quarter. Nisa Investment Advisors LLC grew its position in Insmed by 325.4% in the third quarter. Nisa Investment Advisors LLC now owns 3,595 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 2,750 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Insmed by 20.5% in the second quarter. Charles Schwab Investment Management Inc. now owns 671,587 shares of the biopharmaceutical company’s stock valued at $18,496,000 after acquiring an additional 114,371 shares during the last quarter.

Shares of NASDAQ:INSM traded up $0.35 on Monday, reaching $36.73. The company’s stock had a trading volume of 1,191 shares, compared to its average volume of 934,062. The stock’s 50-day moving average is $36.84 and its two-hundred day moving average is $32.61. Insmed has a 52-week low of $12.09 and a 52-week high of $42.71. The company has a debt-to-equity ratio of 1.03, a current ratio of 7.95 and a quick ratio of 7.43. The stock has a market capitalization of $3.74 billion, a P/E ratio of -13.99 and a beta of 2.45.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Read More: What is a good dividend yield?

Get a free copy of the Zacks research report on Insmed (INSM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.